Hello Guest, Welcome To The Psoriasis Club Forum. We are a self funded friendly group of people who understand.
Never be alone with psoriasis, come and join us. (Members see a lot more than you) LoginRegister
Psoriasis Club is a friendly on-line Forum where people with psoriasis or psoriatic arthritis
can get together and share information, get the latest news, or just chill out with others who understand. It is totally
self funded and we don't rely on drug manufacturers or donations. We are proactive against Spammers,
Trolls, And Cyberbulying and offer a safe friendly atmosphere for our members.
So Who Joins Psoriasis Club?
We have members who have had psoriasis for years and some that are newly diagnosed. Family and friends of those with psoriasis
are also made welcome. You will find some using prescribed treatments and some using the natural approach. There are people who
join but keep a low profile, there are people who just like to help others, and there are some who just like
to escape in the Off Topic Section.
Joining Couldn't Be Easier: If you are a genuine person who would like to meet others who understand,
just hit the Register button and follow the instructions.
Members get more boards and privileges that are not available to guests.
OK So What Is Psoriasis?
Psoriasis is a chronic, autoimmune disease that appears on the skin. It
occurs when the immune system sends out faulty signals that speed up the
growth cycle of skin cells. Psoriasis is not contagious. It commonly
causes red, scaly patches to appear on the skin, although some patients
have no dermatological symptoms. The scaly patches commonly caused by
psoriasis, called psoriatic plaques, are areas of inflammation and
excessive skin production. Skin rapidly accumulates at these sites which
gives it a silvery-white appearance. Plaques frequently occur on the
skin of the elbows and knees, but can affect any area including the
scalp, palms of hands and soles of feet, and genitals. In contrast to
eczema, psoriasis is more likely to be found on the outer side of the
joint.
The disorder is a chronic recurring condition that varies in severity
from minor localized patches to complete body coverage. Fingernails and
toenails are frequently affected (psoriatic nail dystrophy) and can be
seen as an isolated symptom. Psoriasis can also cause inflammation of
the joints, which is known as (psoriatic arthritis). Ten to fifteen
percent of people with psoriasis have psoriatic arthritis.
The cause of psoriasis is not fully understood, but it is believed to
have a genetic component and local psoriatic changes can be triggered by
an injury to the skin known as Koebner phenomenon. Various
environmental factors have been suggested as aggravating to psoriasis
including stress, withdrawal of systemic corticosteroid, excessive
alcohol consumption, and smoking but few have shown statistical
significance. There are many treatments available, but because of its
chronic recurrent nature psoriasis is a challenge to treat. You can find more information
Here!
Got It, So What's The Cure?
Wait Let me stop you there! I'm sorry but there is no cure. There are things that can help you
cope with it but for a cure, you will not find one.
You will always be looking for one, and that is part of the problem with psoriasis There are people who know you will be
desperate to find a cure, and they will tell you exactly what you want to hear in order to get your money. If there is a
cure then a genuine person who has ever suffered with psoriasis would give you the information for free. Most so called cures
are nothing more than a diet and lifestyle change or a very expensive moisturiser. Check out the threads in
Natural Treatments first and save your money.
Great so now what? It's not all bad news, come and join others at Psoriasis Club and talk about it. The best help is from accepting it and talking
with others who understand what you're going through. ask questions read through the threads on here and start claiming
your life back. You should also get yourself an appointment with a dermatologist who will help you find something that can
help you cope with it. What works for some may not work for others
Posted by: Fred - Sat-08-03-2025, 12:15 PM
- Replies (2)
UCB have released Bimzelx (bimekizumab) 5 year data.
Sustained complete skin clearance over five years: In a subset of 153 patients from the second extension of BE BRIGHT, 67.7% of patients with moderate-to-severe plaque psoriasis (PSO) treated with BIMZELX® (bimekizumab-bkzx) achieved PASI100 at five years
Durable and broad efficacy across patient subgroups at four years: Consistently high rates of complete or near-complete skin clearance seen at four years regardless of baseline weight or baseline cardiometabolic comorbidities such as hypertension, hyperglycemia or elevated BMI
High response rates in patients at risk of psoriatic arthritis at three years: Data showed 68.7–71.6% of PSO patients at risk of developing psoriatic arthritis (PsA) achieved complete skin clearance, generally consistent with the overall treated group. Similar results were seen in all patients with PSO, including those with PsA at baseline
Dual inhibition: BIMZELX® is the first and only approved medicine designed to selectively inhibit both interleukin 17A (IL-17A) and interleukin 17F (IL-17F)
Five-year efficacy and safety:
A US/Canadian subgroup of 153 patients completing BE VIVID/BE SURE/BE READY and the BE BRIGHT open-label extension could enter a second 48-week extension (OLE2), where all patients received Q8W. Bimekizumab-bkzx demonstrated high rates of clinical and health-related quality of life responses, which were highly durable to Year 5. It was generally well tolerated in this patient subgroup, with no unexpected safety findings, over five years:
Of the 153 patients analyzed, 75.2% and 67.7% patients achieved PASI100 at one year and five years, respectively. Similarly, 92.8% and 84.9% achieved PASI90 at one year and five years, respectively
Over five years, in the subgroup of 153 patients, the four most common treatment emergent adverse events (TEAEs) were: nasopharyngitis (9.7/100PY), oral candidiasis (7.6/100PY), coronavirus infection (6.1/100PY) and upper respiratory tract infection (5.8/100PY).
Weight stratification:
Bimekizumab-bkzx demonstrated long-term efficacy across four years regardless of patients’ weight subgroup at baseline (either <90 kg or ≥90 kg):
Of the 420 patients analyzed who were <90 kg, 88.5%/67.4% achieved PASI90/PASI100 at four years
Of the 351 patients analyzed who were ≥90 kg, 83.0%/61.6% achieved PASI90/PASI100 at four years
Skin clearance rates in patients with cardiometabolic comorbidities:
High and durable levels of complete or near-complete skin clearance were achieved after four years of bimekizumab-bkzx treatment in 771 patients with PSO, regardless of baseline hypertension, elevated BMI, or hyperglycemia:
Of the 375 patients with baseline hypertension, 82.8%/59.3%, respectively, achieved PASI90/PASI100 at four years
Of the 344 patients with baseline elevated BMI, 82.5%/60.7%, respectively, achieved PASI90/PASI100 at four years
Of the 62 patients with baseline hyperglycemia, 80.4%/56.9%, respectively, achieved PASI90/PASI100 at four years
Patients at risk of progressing to psoriatic arthritis (PsA):
The rates of complete skin clearance (PASI100) were high after three years in bimekizumab-bkzx-treated patients with PSO and risk factors for progression to PsA, or who screened PsA-positive, consistent with the overall bimekizumab-bkzx-treated group. Outcomes were similar when the analysis was restricted to patients with only psoriasis at baseline.
*All patients received bimekizumab-bkzx every four weeks (Q4W) to Week 16, then received either Q4W or Q8W depending upon response to treatment. Receiving Q4W to Week 16, then Q8W thereafter is the approved dosing regimen (Q4W/Q8W). Results included patients receiving both Q4W/Q8W and Q4W/Q4W.
Posted by: Fred - Fri-07-03-2025, 12:45 PM
- Replies (2)
Sotyktu (deucravacitinib) in plaque psoriasis four year safety and efficacy results.
Quote:Background:
Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor, is approved in multiple countries for treatment of adults with moderate to severe plaque psoriasis who are candidates for systemic therapy.
Objectives:
To evaluate the safety and efficacy of deucravacitinib through 4 years in the Phase 3 POETYK PSO-1, PSO-2 and long-term extension (LTE) trials in psoriasis.
Methods:
PSO-1 and PSO-2 (parent trials) randomized patients 1:2:1 to oral placebo, deucravacitinib 6 mg once daily (QD) or apremilast 30 mg twice daily. At 52 weeks, patients enrolled in the LTE trial received open-label deucravacitinib 6 mg QD. Safety was evaluated in patients who received ≥1 dose of deucravacitinib at any time. Clinical and patient-reported outcomes (PASI, PGA and DLQI) were analysed in patients who received continuous deucravacitinib from Day 1 of the parent trials and enrolled in the LTE trial.
Results:
In total, 1519 patients received ≥1 dose of deucravacitinib, with cumulative exposure of 4392.8 person-years (PY) through the data cut-off of 1 November 2023. Exposure-adjusted incidence rates (EAIRs)/100 PY of noted safety measures were comparable or decreased from the 1-year to 4-year cumulative period, respectively, for adverse events (AEs) (229.23, 131.68), serious AEs (including COVID-19) (5.68, 5.01), deaths (0.20, 0.25), discontinuation due to AEs (4.38, 2.20), herpes zoster (0.81, 0.55), malignancies (1.02, 0.89), major adverse cardiovascular events (0.30, 0.32) and venous thromboembolism (0.20, 0.07). In patients who received continuous deucravacitinib (n = 513), clinical and patient-reported outcome rates were well maintained from 1 year through 4 years (e.g. PASI 90, 1 year, 45.6% [95% CI, 41.3%–50.0%], 4 years, 47.5% [42.6%–52.4%]; DLQI 0/1, 1 year, 51.5% [47.1%–55.9%], 4 years, 49.4% [44.4%–54.4%]).
Conclusions:
Deucravacitinib demonstrated a consistent safety profile and durable efficacy through 4 years of treatment in patients with moderate to severe plaque psoriasis.
Posted by: Fred - Wed-05-03-2025, 13:54 PM
- No Replies
This study suggests TYK2 inhibitor could be used in a topical manner on psoriasis therapy.
Quote:Introduction:
Tyrosine kinase 2 (TYK2)-dependent cytokine signalling is integral to the pathogenesis of psoriasis. While BMS-986165, a highly selective TYK2 inhibitor, has recently been approved for oral treatment of psoriasis, its therapeutic potential via topical application remains unexplored.
Objectives:
We aim to investigate the efficacy of topically applying TYK2 inhibitor in psoriasis and to elucidate the underlying mechanisms driving the therapeutic effects of this delivery approach.
Methods:
1.5% BMS-986165 ointment was applied topically to the back skin of imiquimod (IMQ)-induced psoriatic mice. To identify potential target cells influenced by the topical TYK2 inhibitor, we performed single cell RNA sequencing (scRNA-seq) and flow cytometry on mouse lesions. The role of TYK2 in vitro was assessed by silencing its expression or administering BMS-986165 in human keratinocytes (KCs). Mechanistic insights into TYK2 function in KCs were further investigated using RNA-seq, dual luciferase reporter assay and ChIP-qPCR.
Results:
External use of 1.5% BMS-986165 ointment significantly ameliorated the IMQ-induced psoriasis-like dermatitis. Importantly, topical TYK2 inhibitor attenuated proinflammatory capability of KCs. In vitro, TYK2 inhibition suppressed the transcription of nerve growth factor receptor (NGFR) by disrupting the AKT-SP1 signalling pathway. This impairment hindered the activation of activator protein 1 (AP1), thereby weakening the proinflammatory potential of KCs.
Conclusion:
This study reveals a novel therapeutic potential for selective TYK2 inhibitor in topical manner on psoriasis therapy, which might prompt the development of topical treatment for psoriasis. Crucially, our findings provide an underexplored regulatory mechanism of TYK2 inhibitor in psoriasis.
Posted by: Fred - Tue-04-03-2025, 12:43 PM
- Replies (3)
The aim of this study was to assess drug survival and the efficacy of biologics for psoriasis in smokers compared with non-smokers.
Quote:Background:
Smoking is a modifiable risk factor that increases the likelihood of developing psoriasis and the severity of the disease. In recent years, biological therapies have transformed the management of psoriasis. There is conflicting evidence about whether smoking affects the efficacy of biologics. The aim of this study was to assess drug survival and the efficacy of the first biologic for psoriasis in smokers compared with non-smokers.
Methods:
This was a retrospective cohort study using data from the Australasian Psoriasis Registry. Participants with psoriasis who met Pharmaceutical Benefits Scheme eligibility criteria for a biologic (n = 395) were included. Associations between smoking and drug survival or Psoriasis Area and Severity Index (PASI) response were assessed using univariable and multivariable Cox Proportional Hazards regression, controlling for confounders including sex, obesity, psoriatic arthritis, biologic class and baseline PASI.
Results:
The prevalence of current smoking was 24.6% and former smoking was 18.5%. On univariable analysis, smokers were 34% more likely to discontinue treatment compared with non-smokers (p = 0.039), were 27% less likely to attain PASI90 (p = 0.037) and 33% less likely to attain PASI100 (p = 0.038). On multivariable analysis, the association between smoking and reduced drug survival was no longer statistically significant. Multiple factors, including obesity, female sex, psoriatic arthritis and higher PASI scores, were risk factors for drug discontinuation.
Conclusions:
This analysis illustrated that multiple factors are involved in drug survival, and smoking was not an independent risk factor for drug discontinuation. This study provides a rationale for future studies examining the effect of lifestyle modification on the efficacy of biological therapies in psoriasis.
Posted by: Fred - Mon-03-03-2025, 16:10 PM
- Replies (1)
This cohort aimed to explore the association between metabolic syndrome (MetS) and radiographic features (peripheral and axial) in psoriatic arthritis (PsA).
Quote:Objectives:
Metabolic syndrome (MetS) is a known comorbidity of psoriatic arthritis (PsA) and is associated with PsA disease activity. We aimed to explore the association between MetS and radiographic features (peripheral and axial) in PsA.
Methods:
We included patients with PsA followed at our prospective observational cohort for the period between 1978 and 2024. We identified patients with MetS on longitudinal follow-up and used generalized estimating equations (GEE) analysis to define the radiographic features independently associated with MetS, adjusting for age, sex, PsA disease duration, calendar decade, and use of targeted disease modifying anti-rheumatic drugs.
Results:
The study population consisted of 1422 patients, out of which 400 (28.1%) had MetS at baseline (clinic entry) and 836 (58.79%) ever had a record of MetS (per the harmonized definition by Alberti et al.) over a median [interquartile range] follow-up duration of 10.59 [4.52, 18.28] years. The mean (standard deviation [SD]) age of our cohort at baseline was 44.43 (12.98) years, with 789 (55.5%) patients identifying as male. Mean (SD) body mass index was 28.79 (6.36) kg/m2. In the GEE analysis, MetS was not significantly associated with axial disease or radiographic damage to peripheral joints, assessed as the presence of syndesmophytes or sacroiliitis and the radiographic damaged joint count, respectively. On the other hand, MetS was significantly associated with calcaneal spurs, diffuse idiopathic skeletal hyperostosis, and degenerative disc disease.
Conclusion:
MetS is associated with degenerative and metabolic changes in the spine and entheses, but not with radiographic damage in PsA.
Posted by: Fred - Mon-03-03-2025, 16:03 PM
- Replies (2)
This retrospective analysis aimed to establish criteria to accurately approximate Generalized pustular psoriasis (GPP) prevalence in Germany.
Quote:Background and Objectives: Generalized pustular psoriasis (GPP) is a rare, chronic, potentially life-threatening skin disease. We aimed to establish criteria to accurately approximate GPP prevalence in Germany.
Methods: A retrospective analysis of the WIG2 health claims database (1/1/2016–31/12/2020) was conducted. Patients aged ≥ 12 years continuously enrolled in their statutory health insurance with one inpatient or confirmed outpatient diagnosis code for GPP (International Classification of Diseases, 10th Revision [ICD-10] L40.1) were included. Scenarios with increasingly strict criteria were used to identify the GPP population.
Results: From 2016–2020, 5,236 potential GPP cases were identified based on a recorded GPP diagnosis. The scenario of ≥ 1 GPP diagnosis yielded the highest prevalence (336–390 patients/million) followed by > 1 GPP diagnosis in ≥ 2 quarters (189–288 patients/million); scenarios resulting in the lowest prevalence were diagnosis in ≥ 2 quarters AND two independent diagnoses (17–28/million) and diagnosis in ≥ 2 quarters AND two independent diagnoses or diagnosis by a specialist AND potential flare (58–61 patients/million).
Conclusions: This study suggests that diagnosis in ≥ 2 quarters by a specialist or two independent physicians may be the most clinically robust and reliable criteria for estimating GPP prevalence; therefore, 50–100 patients/million may represent a reasonable prevalence estimate range for Germany.
Posted by: Fred - Fri-28-02-2025, 14:09 PM
- No Replies
JumPPP (NCT04451720) was a phase 3, multicenter, randomized, placebo-controlled, parallel-group, double-blind study evaluating the safety and efficacy of Skyrizi in adult Japanese subjects with Moderate-to-severe PalmoPlantar Pustulosis.
Quote:
Palmoplantar pustulosis (PPP) is a chronic, debilitating skin disease of the palms and/or soles. We report the efficacy and safety of risankizumab (RZB), an interleukin 23 p19 inhibitor, from the JumPPP study (a phase 3, multicenter, randomized, placebo-controlled, double-blind study to evaluate RZB in adult Japanese sUbjects with Moderate-to-severe PalmoPlantar Pustulosis; NCT04451720).
Patients were randomized 1:1 to receive RZB (150 mg) or placebo at weeks 0 and 4; all patients received RZB from week 16 to week 52 (patients initially randomized to RZB) or week 56 (patients initially randomized to placebo).
The primary end point was a Palmoplantar Pustulosis Area and Severity Index (PPPASI) change from baseline; secondary end points were ≥50%/≥75% improvement in PPPASI (PPPASI 50/75) at week 16. Efficacy and safety were evaluated to 68 and 76 weeks, respectively. In total, 119 patients (RZB, n = 61; placebo, n = 58) were enrolled. Greater improvement with RZB versus placebo was demonstrated by the significant difference in PPPASI change from baseline at week 16 (least squares mean treatment difference, −3.48; p < 0.05). At week 16, a greater proportion of patients receiving RZB vs placebo achieved PPPASI 50 (41.0% vs 24.1%; nominal p < 0.05) but not PPPASI 75 (13.1% vs 15.5%; nominal p = 0.74). Improvements generally continued through to week 68.
The safety profile was generally consistent with previous studies of RZB in psoriasis. RZB demonstrated efficacy over placebo at week 16 in Japanese patients with PPP, with improvements sustained through to week 68, and was well tolerated with no unexpected safety findings.
Posted by: Fred - Thu-27-02-2025, 17:27 PM
- Replies (2)
This meta-analysis evaluates the efficacy of statins in managing psoriasis severity.
Quote:Background:
Psoriasis, a chronic inflammatory skin disorder, is associated with an elevated risk of cardiovascular diseases due to shared inflammatory pathways. This meta-analysis evaluates the efficacy of statins, known for their lipid-lowering and anti-inflammatory properties, in managing psoriasis severity.
Methods:
A systematic search was conducted following Preferred Reporting Items for Systematic reviews and meta-analysis guidelines across pub med, Cochrane, Web of Science, Scopus, EMBASE, and CINAHL databases up to October 2024. Randomized clinical trials comparing statins with placebo or alternative treatments in adult psoriasis patients were included. The primary outcome was the Psoriasis Area and Severity Index (PASI) score or symptom improvement.
Results:
Out of 11,894 identified articles, 10 randomized clinical trials were included in the final analysis. Data from eight studies with 638 observations revealed a standardized mean difference (SMD) of −0.36 (95% confidence intervals [CI]: −0.72 to 0.00; p = 0.05; I² = 52.0% [95% CI: 0.0% to 79.5%]) for PASI scores, indicating a beneficial effect of statins on psoriasis severity, although not statistically significant. Subgroup analysis demonstrated significant effects for topical administration (SMD = −0.82; 95% CI: −1.47 to −0.16; I2 = 0%). Secondary outcomes, measured using the Dermatology Life Quality Index (DLQI), were assessed in three studies (232 observations) and showed an SMD of 0.24 (95% CI: −0.09 to 0.57; p = 0.1; I2 = 0%), indicating no significant improvement in DLQI scores. Analysis of high-sensitivity C-reactive protein (hsCRP) from two studies (164 observations) revealed an SMD of −0.12 (95% CI: −0.42 to 0.18; p = 0.44; I2 = 0%), indicating no significant reduction in systemic inflammation.
Conclusions:
While statins may reduce psoriasis severity, the meta-analysis did not show statistically significant improvements in PASI scores, except for topical application, and found no significant benefits in DLQI or hsCRP levels. Variability across studies and small sample sizes are notable limitations. Future research with larger cohorts and extended follow-ups is warranted to clarify the potential role of statins in psoriasis management.
Posted by: Fred - Wed-19-02-2025, 15:27 PM
- Replies (2)
Oral, once-daily doses of VYN202 being evaluated in subjects with moderate-to-severe plaque psoriasis.
Quote:
VYNE Therapeutics Inc a clinical-stage biopharmaceutical company focused on developing differentiated therapies to treat chronic inflammatory and immune-mediated conditions with high unmet need, today announced that the first subject has been dosed in a Phase 1b trial evaluating VYN202 in moderate-to-severe plaque psoriasis. VYN202 is an oral small molecule BD2-selective bromodomain and extra-terminal domain (BET) inhibitor that is being developed for the treatment of immune-mediated diseases. The Phase 1b trial will primarily evaluate the safety of VYN202, administered orally once a day for 12 weeks, with secondary objectives to evaluate the pharmacokinetic profile and preliminary evidence of efficacy, including improvement from baseline in psoriasis area and severity index (PASI) scores. Top-line data from the 12-week randomized, placebo-controlled trial are expected by year-end 2025.
“The initiation of the Phase 1b trial in subjects with moderate-to-severe plaque psoriasis represents a major step forward in advancing our novel and highly selective oral BET inhibitor, VYN202,” said David Domzalski, President and Chief Executive Officer of VYNE. “Psoriasis shares common underlying biological pathways with several other chronic inflammatory conditions, and we believe results from this trial will provide key insights into VYN202’s potential use as a novel, once-daily oral treatment for chronic immune-mediated diseases.”
“Our Phase 1a single ascending dose (SAD) and multiple ascending dose (MAD) trial showed that VYN202 had a favorable safety profile and also demonstrated VYN202’s potential to inhibit the production of multiple inflammatory biomarkers related to Th17, TNF and Th1/myeloid dysregulated activity,” said Iain Stuart, PhD, Chief Scientific Officer of VYNE. “We look forward to reporting results from this robust Phase 1b trial by the end of this year.”
Does anyone have experience traveling in Japan with Psoriasis?
I was thinking of going, but read the Japanese see it as somewhat of a 'stigma.' Especially in the public baths, (not that I was considering that.)
I am concerned that it will become too much of a problem since I can't possibly cover-up all of it and I don't know just how much of a stigma it would be.
Hello all,
My name is Scott. I'm 59 and have had psoriasis since I was seven. It didn't take long to get severe, which made my teen years rather challenging. (Diagnosed with Psoriatic arthritis in mid-twenties.) Needless to say I've had quite a few years to learn to deal with it. I have it over most of my body, mostly thin, red, with less flaking, but other spots thicker with lots of flakes. Frankly, I can remember what it was like not to have this disease.
I've been through many doctors, tried many treatments, (no biologics yet,) and don't have much faith in the safety of the newer stuff. (You might say I've become a bit 'jaded' with the medical establishment's approach to treating my condition over the last 50 years.) I feel like my best path is through diet. (Keto or Carnivore.)
For a long while I thought I would go through this life on my own, but at about 30 years old I met a wonderful woman who was able to see past the 'surface' and love me for who I am. We have two kids, and yes, I worry about them developing this condition, but so far it hasn't happened.
I've learned a great about myself and other people in coping with psoriasis, and haven't escaped the emotional and psychological effects I'm sure most of you understand, but all in all, my skin and I have come to an understanding: It's going to do what it's going to do, and I'm not going to let it ruin my life.
I'm very happy to talk to anyone about it on here, so don't be a stranger.
Posted by: Fred - Wed-29-01-2025, 15:09 PM
- Replies (3)
This study looked at sodium in the diet of people with psoriasis.
Quote:Background:
Sodium is stored in skin and may trigger or perpetuate autoimmune diseases including psoriasis. One previous study found skin sodium was elevated in a small group of patients with severe psoriasis compared to healthy controls, but the relationship between sodium intake and psoriasis within a population has not been investigated.
Objectives:
To identify whether dietary sodium intake is associated with psoriasis and whether there are subgroups of individuals more likely to have salt-sensitive psoriasis.
Methods:
This cross-sectional, population-based study evaluated a UK Biobank cohort of nearly 500,000 participants in the 2006–2010 period and a US-based National Health and Nutrition Examination Survey (NHANES) validation cohort of 2393 participants in the 2003–2004 period. Dietary sodium intake, the exposure, was estimated using urine biomarkers and the previously validated INTERSALT equation. Psoriasis outcome was assessed by the presence of ICD-10 code L40.
Results:
In the UK Biobank, of the 468,913 included participants, 54% were female and mean (standard deviation) age at recruitment was 57 (8) years. Multivariable logistic regression models revealed that every 1 g increase in estimated 24-h urine sodium was associated with an 18% increase in odds of psoriasis (OR 1.18, 95% CI: 1.14–1.21) after adjustment for sex, age, race/ethnicity, education and socioeconomic status. There was no consistent evidence of large effect modification by age, sex, race/ethnicity, polygenic risk score for psoriasis or those with a history of hypertension, chronic renal failure or type 2 diabetes mellitus. In NHANES, each additional gram of self-reported dietary sodium intake was also associated with increased odds of examination-confirmed psoriasis (OR: 1.47, 95% CI: 1.19–1.83).
Conclusions:
Increased sodium intake was associated with psoriasis in two population-based cohorts; future clinical trials could investigate whether decreasing sodium intake improves psoriasis.
Source: onlinelibrary.wiley.com
*Funding: National Center for Advancing Translational Sciences
Just dropped in to say the following -two years back left a job of 27 years – and started out on my own, [ had P since a teenager]
Last year my skin was awful - legs / back / trunk - it was tough going, I was applying skin moisturisers twice a day and very, very down.
Not sure why I started –[ I was trying all sorts of creams [ had been to specialists] steroids / beehive lotion you name it etc but always came back ] – but I think I read somewhere about the properties & minerals of the ocean –
so last August I started swimming in the sea – I live in the SE of Ireland . From the first swim I felt better, now 5 months on I try to swim for 5 minutes a day [ warm shower after with a cold rinse ] and my skin is 90% better ! [some days just a small cold shower if the sea is too rough]
Not sure if it’s the cold water reduces stress levels that is the reason – but I swear its addictive and healing.
Ive not been active here for a long time. I started Uvb treatment back in March i believe.
It was great. Within probably 2 or 3 months i was nearly clear (90+%) after having bad 90%+ coverage with horrible scales. I had a few flares here and there but the treatment would zap the new psoriasis fast. I was doping 3 treatments a week. A few months ago now my doc dropped me to once a week and since then the PSO has been growing and growing again. Cold weather in Canada doesnt help.
The derm wants to take me off it. She says its not wise to keep me on it long term due to risk of cancer. But i won't go on meds and since getting a taste of clear skin im seriously considering getting my own home unit and using it conservatively. No more than 3 times a week, very short period, like a minute per side. Being careful to avoid any burning or skin irritation.
Admittedly i am a little distrustful of the derm, shes nice but shes very pharmaceutical focused and personally i dont trust and wont touch the stuff. When i started the phototherapy she told me they have 30+ years of data on UVB and that its safe, effective and doesn't have much cancer risk. But that the most data they have on biologics is 8 years. But shes pushed me very hard to go that route. I have very persistent psoriasis, we both know that the other drugs you have to go through before biologics wont work but you know... gotta follow the "protocol". I also really don't like this and it makes me very skeptical and distrustful when it comes to the way derms treat pso.
I am a person who responds well to sun, i dont burn easy. Phototherapy has been great for me. Like a miracle. But its clear 1 treatment a week, especially during the winter, isnt enough and my derm has already told me i HAVE to come off soon.
I am not looking for medical advice, but wondering if anyone has used uvb long term? I would think using it every other day indefinitely is a poor idea but using it more or less (without going overboard) as needed seasonally might be a reasonable method of treatment.
What do we think? Anyone use UVB at home? Looking for feeback and insight from people who have lots of experience with UVB.
Posted by: Fred - Sat-04-01-2025, 12:14 PM
- No Replies
Qyuns Therapeutics are developing QX004N, an IL-23p19 inhibitor for psoriasis. This is the results of a randomized clinical trial looking at it's safety and efficacy as a treatment for patients with moderate to severe plaque psoriasis.
Quote:
Objective To assess the safety, pharmacokinetics, and efficacy of QX004N in healthy individuals and patients with moderate to severe plaque psoriasis in China.
Design, Setting, and Participants This randomized clinical trial was composed of 2 parts. Part 1 was a first-in-human, single-ascending-dose, phase 1a clinical trial conducted from November 2, 2021, to January 16, 2023. Part 2 was a double-blind, multiple dose-escalation, phase 1b clinical trial conducted from February 15, 2023, to January 5, 2024, at 5 clinical centers in China, involving patients with moderate to severe plaque psoriasis.
Interventions In part 1, healthy participants in each cohort were assigned in a 4:1 ratio to receive a single subcutaneous injection of QX004N (ranging from 10 mg to 600 mg) or placebo. In part 2, patients in each cohort were assigned in a 4:1 ratio to receive QX004N or placebo at doses of 150 mg, 300 mg, and 600 mg once every 2 weeks.
Main Outcomes and Measures For part 1, the primary outcome was the safety of a single dose of QX004N in healthy participants, and the secondary outcome was the pharmacokinetic profile. For part 2, the primary efficacy end point was the proportion of patients achieving at least 75% improvement in Psoriasis Area and Severity Index (PASI 75) by week 12; other efficacy end points were considered secondary.
Results The phase 1a clinical trial (part 1) enrolled 55 healthy participants (mean [SD] age, 35.9 [6.0] years; 30 [54.5%] female), and the phase 1b clinical trial (part 2) enrolled 30 patients with moderate to severe plaque psoriasis. The mean (SD) age of QX004N-treated participants in part 2 was 41.4 (7.5) years, and 19 of 24 QX004N-treated participants (79.2%) were male. The mean (SD) age of the placebo cohort in part 2 was 35.3 (8.4) years, and 5 of 6 placebo-treated participants (83.3%) were male. QX004N exhibited linear pharmacokinetics and was tolerated well in both healthy participants and patients with psoriasis. Most adverse events were mild to moderate in severity, with no drug-related serious adverse events reported. The proportion of patients receiving QX004N who achieved PASI 75 at week 12 and PASI 90 (90% improvement in PASI) at week 16 in the 150-mg, 300-mg, and 600-mg cohorts was 100%, significantly higher than that in the placebo cohorts (33.3%). The maximum proportion of patients achieving Investigator’s Global Assessment score of 0 or 1 was 100% in the 3 QX004N cohorts.
Conclusions and Relevance In this randomized clinical trial, QX004N was well tolerated and demonstrated superior efficacy compared to placebo in patients with moderate to severe plaque psoriasis.
Has anyone switched from Stelara to Humira due to Psoriatic Arthritis?
PsA symptoms started a few months back. Had my appointment with the rheumatologist this morning. They suggested methotrexate first, which I shut down immediately as it didn't work for my psoriasis. They then prescribed Humira. Has anyone else made this switch, and how did you find it? Would also appreciate if anyone on Humira could let me know their experience on it.
Sorry, I haven't been on here in quite some time- this is such a good group for support of psoriasis sufferers.
I feel I need to share my journey in case it can help someone.
I've had plaque psoriasis for about 40 years, since I was in my 20s. Have had "several" general practitioners and dermatologists these years. Tried all of the creams and ointments, light treatments, etc with no real improvement.
I've had the theory for a while that it was something I was eating that was not agreeing with my system, but Every Single Doctor I asked said the diet has no effect on skin.
Well, I saw a kinesiologist this summer to help me with IBS, and he was able to do a food sensitivity test for me. Turns out I'm very sensitive to all dairy, all yeast, several fruits and vegetables, sugar. With this knowledge I started on a carnivore diet - meat and eggs, including fish - to help with IBS because that was making me miserable.
Bonus! Yes, my IBS is 90% improved - but the amazing thing is that my psoriasis is GONE. I still have some scarring, but I am not flaking off huge chunks of skin, and overall my skin feels so much better. And for an old lady this is miraculous!!!
And this is just in the past 4 months. I'm going to continue this way of eating because I feel so much better overall (obviously removing things like milk and bread that were trying to kill me -will have that effect!) It was difficult at first, but now that I'm past the initial cravings etc, it's much easier to go to the grocery. Stay to the outside, don't give in to temptation down the aisles!!!
Posted by: Fred - Tue-24-12-2024, 11:59 AM
- No Replies
Bristol Myers Squibb announces positive topline results from two pivotal phase 3 trials evaluating Sotyktu (deucravacitinib) in adults with psoriatic arthritis.
Quote:
Bristol Myers Squibb today announced results from POETYK PsA-1 (IM011-054) and POETYK PsA-2 (IM011-055), the pivotal Phase 3 trials evaluating the efficacy and safety of Sotyktu (deucravacitinib) in adults with active psoriatic arthritis (PsA). Both trials met their primary endpoint, with a significantly greater proportion of Sotyktu -treated patients achieving ACR20 response (at least a 20 percent improvement in signs and symptoms of disease) after 16 weeks of treatment compared with placebo.
Additionally, the POETYK PsA-1 and POETYK PsA-2 trials met important secondary endpoints across PsA disease activity at Week 16. The overall safety profile of Sotyktu through 16 weeks of treatment in the POETYK PsA-1 and POETYK PsA-2 trials was consistent with the established safety profile of Sotyktu observed in a Phase 2 PsA clinical trial and Phase 3 moderate-to-severe plaque psoriasis clinical trials.
"Psoriatic arthritis is a heterogenous disease that causes a range of different symptoms, including joint pain and swelling, as well as psoriatic skin lesions. Despite available therapies, rheumatologists continue to express a need for a safe and effective oral treatment," said Roland Chen, MD, senior vice president and head, Immunology, Cardiovascular and Neuroscience development, Bristol Myers Squibb. "These POETYK PsA-1 and POETYK PsA-2 findings demonstrate that oral Sotyktu has the potential to be the first TYK2 inhibitor for people living with psoriatic arthritis and reinforce the established efficacy and safety profile of Sotyktu . We are encouraged by the positive data across both Phase 3 trials and look forward to discussing the results with health authorities."
Bristol Myers Squibb will work with key investigators to present detailed results at upcoming medical congresses.
These topline results represent the first Phase 3 clinical trials for Sotyktu in a rheumatic condition. Sotyktu is approved in numerous countries around the world for the treatment of adults with moderate-to-severe plaque psoriasis.
Bristol Myers Squibb thanks the patients, investigators and clinical trial sites who participated in these clinical trials.
Posted by: Fred - Sat-14-12-2024, 14:29 PM
- Replies (12)
AbbVie have paid $200 million to get Nimble Therapeutics investigational oral peptide IL23R inhibitor in preclinical development for the treatment of psoriasis.
Quote:
IL-23 is a cytokine that activates Th17 cells, promoting an inflammatory response that contributes to tissue damage and organ dysfunction.
IL-23R is a receptor involved in the IL-23/IL-17 immune pathway, crucial in the pathogenesis of psoriasis and IBD. Upregulation of IL-23R expression is associated with increased susceptibility to IL-23 signaling, amplifying inflammation and immune responses in psoriasis and inflammatory bowel diseases (IBD), and underpinning the significant clinical efficacy of IL-23 blocking antibodies in these diseases. IL-23R antagonists block the interaction between IL-23 and its receptor, inhibiting the Th17 inflammatory pathway, cytokine production and IL23R upregulation, alleviating inflammation.
We are developing an innovative oral IL-23R antagonist by combining potent activity with gut stability and extended half-life. This medication will offer a more effective oral therapy option for patients seeking less invasive, more effective and convenient treatments.
I had a dermatology appointment yesterday. I'm seeing this doctor annually now that I've learned how to manage my psoriasis and am doing okay. I'm just so grateful to her. She is thorough and smart and committed to relieving suffering. This person could have risen to the top in any field, but she chose skin and her dedication to years of medical education and the care she has provided to me have helped me (along with many others, of course). I am better. I guess I just want to acknowledge this.
But as I get older, I think there's gonna be annual biopsies for skin cancer, too. I have two sore spots now, covered in bandages from yesterday's punch biopsies.
Maybe in the long run, having psoriasis lowers my chances of dying from skin cancer since it will be checked for regularly. I might not have ever seen a dermatologist if I didn't get psoriasis.
You have to register before you can post on our site.
Members Images
Join Psoriasis Club
Psoriasis Club is self funded, we don't rely on sponsorship or donations. We offer a safe
friendly forum and are proactive against spammers, trolls, and cyberbullying. Join us here!
No Advertising.
No Corprate Sponsors.
No Requests for Donations.
No Cyber-Bullying.
No Scams or Cures.
No Recruitment Posts.
No promotions or offers.
No Trolls.
No Spam.
Just a small bunch of friendly people with psoriasis sharing information and support.
Forum Statistics
» Members: 979 » Latest member: xabirett737 » Forum threads: 7,300 » Forum posts: 266,784
There are currently 91 online users. »0 Member(s) | 90 Guest(s) "YOYO" The Psoriasis Club Bot Is On-line
Psoriasis Cure!
How many people have Psoriasis?
In 2012 there were approximately 36.5 million prevalent cases of psoriasis, and by 2022, GlobalData epidemiologists forecast that this figure will reach approximately 40.93 million.
The condition affects individuals of both sexes and all ethnicities and ages, although there is a higher prevalence of psoriasis in the colder, northern regions of the world.
The prevalence of psoriasis in the central region of Italy is 2.8 times greater than the prevalence in southern Italy.
Caucasians have a higher prevalence of psoriasis compared with African-Americans, but African-Americans in the US tend to suffer from a more severe form of the disease.
